Compare Moderna, Inc. (MRNA) vs TJX Companies Inc (TJX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs TJX Companies Inc — how do they compare? Moderna, Inc. trades at $59.66 (market cap $23.60B), while TJX Companies Inc trades at $154.6 (market cap $172.00B). The key difference: TJX Companies Inc is far larger — about 7.3× Moderna, Inc.'s market cap, and TJX Companies Inc pays a 1.23% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | TJX | |
|---|---|---|
Market Cap | $23.60B | $172.00B |
Sector | Health | Consumer Cyclical |
52-Week High | $81.80 | $168.41 |
52-Week Low | $22.36 | $124.53 |
Enterprise Value | $19.70B | $180.60B |
Dividend Yield | — | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.
Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.
TJX trades at $155.00, up 0.4% on the day, with a bullish technical outlook supported by moving averages and strong fundamental performance. The company reported revenue of $56.36 billion in 2025 with a net income margin of 9.4%, and has consistently beaten EPS estimates in recent quarters. Recent news highlights TJX as a beneficiary of shifting retail trends and economic uncertainty.
The outlook for TJX remains positive, driven by earnings growth, international expansion, and strong analyst support with a consensus price target of $181.80. Key risks include competitive pressures in discount retail and sensitivity to consumer spending fluctuations, but the company's robust cash flow and dividend payments provide stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →
